Cargando…
Inclusion of molecular monitoring (BCR-ABL1) in the treatment of chronic myeloid leukemia in the Brazilian Public Health System (SUS): an urgent need for treatment management
INTRODUCTION: Chronic Myeloid Leukemia (CML) is a myeloproliferative disease that affects mainly adults between 50 and 55 years. In Brazil, information from the Sistema Único de Saúde (SUS) Outpatient Information System indicates that 12,531 patients had the Autorização de Procedimento Ambulatorial...
Autores principales: | Boquimpani, Carla Maria, Abdo, André Neder Ramires, Martins, Denise Pires, Lima, Luciana Britto de Abreu, Torriani, Mayde Seadi, Bendit, Israel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Sociedade Brasileira de Hematologia e Hemoterapia
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7910181/ https://www.ncbi.nlm.nih.gov/pubmed/32475788 http://dx.doi.org/10.1016/j.htct.2020.02.002 |
Ejemplares similares
-
Molecular measurement of BCR-ABL transcript variations in chronic myeloid leukemia patients in cytogenetic remission
por: Serpa, Mariana, et al.
Publicado: (2010) -
Monitoring of BCR-ABL levels in chronic myeloid leukemia patients treated with imatinib in the chronic phase - the importance of a major molecular response
por: Machado, Melissa Pereira, et al.
Publicado: (2011) -
Comparative study of different methodologies to detect the JAK2 V617F mutation in chronic BCR-ABL1 negative myeloproliferative neoplasms
por: Didone, Alline, et al.
Publicado: (2015) -
Bcr-Abl Tyrosine Kinase Inhibitors in the Treatment of Pediatric CML
por: Carofiglio, Francesca, et al.
Publicado: (2020) -
Allosteric inhibition enhances the efficacy of ABL kinase inhibitors to target unmutated BCR-ABL and BCR-ABL-T315I
por: Mian, Afsar Ali, et al.
Publicado: (2012)